The Antitumor Effect and Hepatotoxicity of a Hexokinase II Inhibitor 3-Bromopyruvate: In Vivo Investigation of Intraarterial Administration in a Rabbit VX2 Hepatoma Model by Jae, Hwan Jun et al.
596 Korean J Radiol 10(6), Nov/Dec 2009
The Antitumor Effect and Hepatotoxicity
of a Hexokinase II Inhibitor 
3-Bromopyruvate: In Vivo Investigation of
Intraarterial Administration in a Rabbit
VX2 Hepatoma Model
Objective: The purpose of this study was to compare the antitumor effect and
hepatotoxicity of an intraarterial delivery of low-dose and high-dose 3-bromopyru-
vate (3-BrPA) and those of a conventional Lipiodol-doxorubicin emulsion in a rab-
bit VX2 hepatoma model.
Materials and Methods: This experiment was approved by the animal care
committee at our institution. VX2 carcinoma was implanted in the livers of 36 rab-
bits. Transcatheter intraarterial administration was performed using low dose 3-
BrPA (25 mL in a 1 mM concentration, n = 10), high dose 3-BrPA (25 mL in a 5
mM concentration, n = 10) and Lipiodol-doxorubicin emulsion (1.6 mg doxoru-
bicin/0.4 mL Lipiodol, n = 10), and six rabbits were treated with normal saline
alone as a control group. One week later, the proportion of tumor necrosis was
calculated based on histopathologic examination. The hepatotoxicity was evalu-
ated by biochemical analysis. The differences between these groups were statis-
tically assessed with using Mann-Whitney U tests and Kruskal-Wallis tests.
Results: The tumor necrosis rate was significantly higher in the high dose
group (93% ± 7.6 [mean ± SD]) than that in the control group (48% ± 21.7) (p =
0.0002), but the tumor necrosis rate was not significantly higher in the low dose
group (62% ± 20.0) (p = 0.2780). However, the tumor necrosis rate of the high
dose group was significantly lower than that of the Lipiodol-doxorubicin treatment
group (99% ± 2.7) (p = 0.0015). The hepatotoxicity observed in the 3-BrPA
groups was comparable to that of the Lipiodol-doxorubicin group.
Conclusion: Even though intraarterial delivery of 3-BrPA shows a dose-related
antitumor effect, single session treatment seems to have limited efficacy when
compared with the conventional method. 
epatocellular carcinoma (HCC) is one of the most common malignant
tumors in the world and the estimated number of cancer-related deaths
currently exceeds 500,000 per year (1, 2). Although surgery is the
preferred treatment for HCC, only 10-20% of all patients with HCC are suitable
candidates for either hepatic resection or transplantation because of tumor extension,
poor hepatic function or both (3-5). Among several therapeutic options that have
been advocated for the treatment of unresectable HCC, transcatheter arterial
chemoembolization (TACE) has been widely performed and various cytotoxic agents
have been used, including doxorubicin, cisplatin and 5-fluorouracil. However the
therapeutic efficacy of TACE is still limited and the overall results of treatments for
HCC remain unsatisfactory (6). Therefore, a new therapeutic strategy is needed for
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Hthe management of HCC. 
One of the most common and profound biochemical
phenotypes of animal and human cancer cells is their
ability to metabolize glucose at high rates, and even under
aerobic conditions (7-10). In contrast to normal cells,
tumor cells are mainly dependent on the glycolysis
pathway for meeting their adenosine triphosphate (ATP)
requirements. Moreover, glycolytic intermediates are
important precursors for the biosynthesis of lipids and
nucleic acids that are essential for cell growth and division
(11). Hexokinase is one of the most important enzymes for
maintaining a high rate of glycolytic energy-production.
This enzyme phosphorylates the incoming glucose to
glucose-6-phosphate, thus trapping the substrate intracellu-
larly and committing it to further glycolysis. Among the
four-hexokinase isotypes (hexokinase I-IV) in mammalian
tissues (12), hexokinase II, which is located on the outer
mitochondrial membrane, is frequently the predominant
overexpressed form in malignant cells, including HCC (13-
16), and hexokinase II normally exists in adipose and
muscle tissues (12, 17).
3-bromopyruvate (3-BrPA) is a pyruvate analog and a
strong alkylating agent, and it was recently found to be a
potent inhibitor of glycolysis and oxidative phosphoryla-
tion by targeting hexokinase II in in vitro experiments with
using rat AS-30D cells and rabbit VX2 carcinoma cells (18-
22). In an in vivo experiment using a VX2 carcinoma cells
and AS-30D cells implanted in rabbit’s liver and rats’
abdomens, respectively, the intraarterial, intravenous and
intraperitoneal delivery of 3-BrPA has showed significant
anticancer effects without damage to normal tissues (19,
22). Therefore, the blockage of energy metabolism by
hexokinase II inhibitors seems to be a promising strategy
to treat highly malignant tumors. 
According to several recent experimental studies
concerned with the intraarterial administration of 3-BrPA
in liver cancer, a single session of 3-BrPA injection showed
no significant antitumor effect compared with that of saline
injection (23) and Vali et al. (24) determined the optimal
therapeutic dose of 3-BrPA. However, to the best of our
knowledge, the therapeutic efficacy of 3-BrPA in compari-
son with doxorubicin, which is a currently established
agent in TACE, has not yet been evaluated. 
The purpose of this study was to evaluate the antitumor
effects and hepatotoxicity of intraarterial delivery of low-
dose 3-BrPA and high-dose 3-BrPA and to compare them
with the antitumor effects and hepatotoxicity of TACE
with using an established chemotherapeutic agent doxoru-
bicin hydrochloride and iodized oil in a rabbit VX2
hepatoma model. 
MATERIALS AND METHODS
Preparation of the 3-BrPA Solutions
The 3-BrPA (Sigma Chemical Co., St. Louis, MO)
solutions were prepared in phosphate buffer solution (PBS)
and then they were adjusted to pH 7.4 with sodium
hydroxide (NAOH). The solutions were sterilized with
using a 0.2 μ m filter unit (Sartorius’ Minisart, Cat.
No.16534). 3-BrPA solutions with 1 mM and 5 mM
concentrations were prepared by mixing the 3-BrPA with
a sterile PBS just before intraarterial infusion, and the
solutions were used immediately. We used a freshly made
3-BrPA solution in all the experiments because of chemical
instability.
The Rabbit VX2 Liver Tumor Model and the
Experimental Groups
This experiment was approved by the animal care
committee of our institution. A total of 36 adult New
Zealand white rabbits weighing 2.5-3.0 kg each were used
for this experiment. The VX2 carcinoma strain had been
maintained by successive transplantations into the hind
limb of a carrier rabbit.
Anesthesia was introduced through an intramuscular
injection of 50 mg of ketamine hydrochloride (Ketalar
�;
Yuhan Yanghang, Seoul, Korea) and 20 mg of xylazine
hydrochloride (Rompun
�; Bayer Korea, Seoul, Korea) at
0.5 mL per kilogram of body weight. After making a
midline subxyphoid abdominal incision, 0.1 mL of minced
VX2 carcinoma was directly implanted into the subcapsu-
lar parenchyma of the left medial lobe of the liver. All the
procedures were performed aseptically. The tumors were
allowed to grow for 2-3 weeks to attain a size of 15-30
mm in diameter.
One day prior to the intraarterial injection of the agents,
a liver computed tomography (CT) scan was performed
(MX 8000; Philips Medical Systems, Best, The
Netherlands) with the animals in the supine position. Non-
enhanced CT was performed to localize the liver. For
contrast material-enhanced CT, 13 mL of contrast material
(iopromide, Ultravist; Schering, Berlin, Germany) was
injected at a rate of 0.5 mL/sec through the auricular vein.
With using the bolus tracking technique, a hepatic arterial
phase scan and a portal venous phase scan were obtained
at approximately 7-8 seconds and 24-25 seconds respec-
tively, after the injection of the contrast media. The
scanning parameters we used were 3-mm collimation, 1.5
pitch and a 1-mm reconstruction interval.
On the CT scan, the location and size of the tumor were
measured by two authors working in consensus. The
volume (V) of the tumor was calculated according to the
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2/2, where L is the longest diameter
and S is the shortest diameter of the tumor (25, 26). The
animals with similar-size tumors were distributed evenly to
each group on the basis of the calculated tumor volume
because the results of antitumor treatment can be
influenced by the tumor volume (27, 28). Thirty-six rabbits
were divided into four groups according to the intraarteri-
ally administered agents as follows: low dose 3-BrPA (25
mL in a 1 mM concentration, n = 10), high dose 3-BrPA
(25 mL in a 5 mM concentration, n = 10), a Lipiodol
(Andre Guerbet, Aulnay-sous-Bois, France)-doxorubicin
(Adriamycin; Il Dong Pharmaceutical Co, Seoul, Korea)
emulsion (1.6 mg doxorubicin/0.4 mL Lipiodol, n = 10)
and the control group (25 mL normal saline, n = 6). The
volumes of tumors were 3,977.9 mm
3 ± 2,268.6 [mean ±
standard deviation [SD]) with the low dose 3-BrPA (n =
10), 2,988.9 mm
3 ± 2,921.1 with high dose 3-BrPA (n =
10), 4,360.3 mm
3 ± 3,658.7 with Lipiodol-doxorubicin
emulsion (n = 10) and 2,648.1 mm
3 ± 2,374.6 in the
control group (n = 6). The tumor volumes were not statisti-
cally different among the four groups (Kruskal-Wallis test,
p = 0.3869).
The rabbits were sacrificed for histologic investigation
with a lethal dose (90 mg/kg) of intravenously adminis-
tered sodium pentobarbital (Pentothal; Choong Wae
Pharmacy, Seoul, Korea) at seven days after the intraarter-
ial procedure. 
Transcatheter Intraarterial Administration
Transcatheter intraarterial administration was performed
under fluoroscopic guidance by two authors who worked
as a team. The same anesthesia protocol as carcinoma
implantation was used, and the right femoral artery was
exposed. A 5-Fr diameter dilator, as a substitute for an
arterial sheath, was inserted into the right femoral vein.
With using a 2.4-Fr microcatheter (Progreat; Terumo,
Tokyo, Japan), celiac angiography was performed to
identify the hepatic arterial anatomy and the feeder artery
of the tumor. The left hepatic artery, which exclusively
supplied blood flow to the tumor, was selectively catheter-
ized. After the catheter was advanced to an adequate
position in the left hepatic artery, the prepared 3-BrPA
solution or normal saline was then infused for 2 minutes.
The Lipiodol-doxorubicin emulsion was carefully injected
to avoid efflux of the embolic materials out of the artery.
The catheter was then removed and the femoral artery was
ligated.
Evaluation of the Antitumor Effects
The antitumor effect was evaluated according to the
tumor necrosis rates that were assessed by microscopic
methods. The rabbits were sacrificed at seven days after
transcatheter intraarterial administration and the livers of
the rabbits were explanted and fixed in 10% buffered
formaldehyde solution. The part of the liver that contained
the tumor was sliced at 5 mm-intervals in the axial plane
that corresponded to the plane of the CT scan, and the
sections were completely embedded in paraffin for
histologic examination, and after which the 4 μ m-thick
sections were stained with hematoxylin and eosin. The
histologic changes and the extent of necrosis in the tumors
were evaluated by an experienced board-certified patholo-
gist. To quantify the antitumor effects, the proportion of
the necrotic area relative to the entire tumor area was
estimated with using Image-Pro Plus software (Media
Cybernetics, Silver Spring, MD). The overall percentage of
viable tumor was calculated based on the average of the
percentage of viable tumor in each slice.
Measurement of Plasma Biochemicals
To determine the hepatic toxicities caused by the
treatment, peripheral blood was drawn from the auricular
vein in all the animals before and at 1, 2 and 7 days after
intraarterial administration. The plasma aspartate
aminotransferase (AST) level and the plasma alanine
aminotransferase (ALT) level were measured with using a
biochemical autoanalyzer (Hitachi Koki, Tokyo, Japan).
Statistical Analysis
The SPSS software package (version 11.0; SPSS,
Chicago, IL) was used for statistical data analysis. The
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Fig. 1. Tumor necrosis rates (%) of experimental groups
(expressed as mean tumor necrosis rate ± SD). Tumor necrosis
rate was significantly higher in high dose group (93% ± 7.6) than
that in control group (48% ± 21.7) (p = 0.0002), but tumor
necrosis rate was not significantly higher in low dose group (62%
± 20.0) (p = 0.2780). However, tumor necrosis rate of high dose
group was significantly lower than that of Lipiodol-doxorubicin
treatment group (99% ± 2.7) (p = 0.0015).Mann-Whitney U test and the Kruskal-Wallis test were
applied to assess the statistical significance of the tumor
necrosis rates and the plasma biochemical levels among the
experimental groups. Statistical significance was set at p
values < 0.05.
RESULTS
Antitumor Effect of Transcatheter Intraarterial
Administration
Transcatheter intraarterial administration was success-
fully performed in all animals, and none of the animals
died during the experimental period. The tumor necrosis
rates of the low dose 3-BrPA group (1 mM concentration,
n = 10), the high dose 3-BrPA group (5 mM concentration,
n = 10), the Lipiodol-doxorubicin emulsion group (0.4 mL
Lipiodol /1.6 mg doxorubicin, n = 10) and the control
group (25 mL normal saline, n = 6) are shown in Figure 1.
Compared with the tumor necrosis rates of the control
group (48% ± 21.7), those of the low dose 3-BrPA group
(62% ± 20.0) did not show a statistically significant differ-
ence (p = 0.2780) (Fig. 2). But the high dose 3-BrPA group
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AB
Fig. 2. Representative case of 3-BrPA 1 mM group. 
A. Contrast-enhanced CT image obtained one day before intraarterial administration shows low attenuated VX2 carcinoma in left hepatic
lobe of rabbit (arrow).
B. On selective left hepatic angiography that was done just before transcatheter intraarterial administration, hypervascular tumor staining
is seen in left hepatic lobe (arrows). After microcatheter was advanced to left hepatic artery, low dose 3-BrPA solution (25 mL in 1 mM
concentration) was infused for 2 minutes.
C. Photograph of resected specimen of tumor. Pathologic specimens containing tumor were sectioned in same transverse plane that
was used for CT scan with 5-mm intervals, and slice with largest tumor area was embedded in paraffin for histologic examination.
D. Photomicroscopic slide of same specimen (Hematoxylin & Eosin staining, ×1). Necrosis rate of tumor is 81%. 
CD(93% ± 7.6) (Fig. 3) and the Lipiodol-doxorubicin
emulsion group (99% ± 2.7) showed higher tumor
necrosis rates than that of the control group with statistical
significance (p = 0.0002 and p = 0.0002, respectively). The
complete eradication of the tumor was achieved only in
the animals in the Lipiodol-doxorubicin emulsion group (n
= 5). The tumor necrosis rate of the Lipiodol-doxorubicin
emulsion group was significantly higher than that of the
high dose 3-BrPA group (p = 0.0015). Therefore, the
antitumor effect in the conventional TACE with Lipiodol-
doxorubicin emulsion group is superior to that of the high
dose 3-BrPA group.
Hepatotoxicity
Figure 4 shows the plasma (AST) level and the plasma
level (ALT) before and at 1, 2 and 7 days after intraarterial
administration. For both AST and ALT, the enzyme levels
were elevated at the first day and then they decreased to
levels close to normal at seven days after intraarterial
administration. The levels of AST and ALT in the high
dose 3-BrPA group and the Lipiodol-doxorubicin emulsion
group were significantly elevated compared to those levels
of the control group at one day (Kruskal-Wallis test, p <
0.05), whereas those levels of the low dose 3-BrPA group
did not show a statistically significant difference compared
with those levels of the control group (p > 0.05). There was
also no significant difference between both the AST and
ALT enzyme levels of the high dose 3-BrPA group and
those levels of the Lipiodol-doxorubicin emulsion group (p
> 0.05). 
DISCUSSION
Although rabbit VX2 carcinoma did not originate from
hepatocytes, it has been widely used as an experimental
model for HCC because of its exclusive hepatic arterial
supply and rapid growth pattern. Moreover, according to
the reports about the biochemical characteristics of VX2
Jae et al.
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Fig. 3. Representative case of 3-BrPA 5 mM group.
A. Contrast-enhanced CT image obtained one day before intraarterial administration shows low attenuated mass with enhancing rim in
left hepatic lobe (arrow).
B. On selective hepatic arteriography, hypervascular tumor staining is seen in left hepatic lobe (arrows).
C. Photograph of resected specimen of tumor.
D. Photomicroscopic slide of same specimen (Hematoxylin & Eosin staining, ×1). Necrosis rate of tumor is 99%.
CDtumor, its glucose metabolic characteristics are similar to
those of human HCC, with a high glycolytic/high hexoki-
nase phenotype (8, 9, 20). These findings suggest that the
rabbit VX2 hepatoma model can be used for evaluating the
therapeutic effect of hexokinase inhibitor, which has the
possibility to be an antitumor agent for HCC.
Hepatic arterial administration of 3-BrPA is a more
efficient drug delivery method for treating hepatic tumors
by providing regional delivery of 3-BrPA while avoiding
the concomitant systemic toxicity. Furthermore, the
normal liver parenchyma receives a dual blood supply
from the hepatic artery and the portal vein, and the
hepatic tumors are almost exclusively supplied by the
hepatic artery. Therefore, hepatic arterial injection of 3-
BrPA can attack hepatic tumors at a higher concentration
and the damage to the normal liver tissue is minimized.
Geschwind et al. (22) reported that treatment with a
single intraarterial injection of 3-BrPA (25 mL in a 0.5 mM
concentration) achieved an 84% average tumor necrosis
rate in the VX2 hepatoma model, as compared with a 26%
average tumor necrosis rate in the nontreated control
group. However, in our study, we failed to demonstrate
significant anti-tumor effects after an intraarterial injection
of low-dose 3-BrPA (25 mL in a 1 mM concentration),
when compared with the injection of normal saline (61%
versus 48%, respectively). The discrepancy between the
studies may be explained in different ways. 3-BrPA is
chemically unstable and its cellular uptake and biodistribu-
tion after intraarterial injection have not been clarified. 3-
BrPA may undergo rapid neutralization if it encounters
blood flow. After intraarterial injection of 3-BrPA, the
concentration of 3-BrPA reaching the tumor vessels can be
decreased due to dilution, to a variable degree, according
to the amount of pericatheter flow. Another explanation is
the possible ischemic necrosis of VX2 tumors in our control
group during normal saline injection. This result is in
accord with that of a previous study by Shin et al, in which
the mean tumor necrosis rate in the saline group reached
up to 68% (23). The authors inferred that the catheter that
was nearly wedged in the small lumen of the hepatic artery
induced a temporary occlusion of the hepatic artery and
therefore this caused ischemic damage to the tumor (23). 
In our study, we could demonstrate significant anti-
tumor effects after intraarterial injection of high-dose 3-
BrPA (25 mL in a 5 mM concentration). However, the
achieved tumor necrosis rate was significantly lower than
that of the established Lipiodol-doxorubicin emulsion
(93% versus 99%, respectively). The limited therapeutic
efficacy of a single intraarterial injection of 3-BrPA
requires further development of a formulation that’s
suitable for intraarterial administration, and effort are
needed to optimize the injection protocols for the injection
duration and concentration, the total injected amount and
the number of sessions and the interval between sessions.
Of course, the mechanisms of cellular uptake, biodistribu-
tion and actions of 3-BrPA should be clarified with further
investigations. As mechanisms of cell death, Gwak et al.
(29) have shown that 3-BrPA induced apoptosis of HCC
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Fig. 4. Biochemical analysis of liver enzymes; mean values of liver enzymes in each group. Line graph shows that aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT) levels tended to transiently increase at one day after intraarterial administration and
they decreased to levels close to normal at seven days. Levels of AST and ALT of high dose 3-BrPA group and Lipiodol-doxorubicin
emulsion group were significantly elevated as compared to those levels of control group at one day, whereas those levels of low dose 3-
BrPA group did not show statistically significant difference as compared with those levels of control group. There was also no significant
difference between both AST and ALT enzyme levels of high dose 3-BrPA group and those of Lipiodol-doxorubicin emulsion group.
A. AST levels. 
B. ALT levels. 
ABcell lines through activating the mitochondrial apoptotic
signaling cascades. HCC cells have been shown to exhibit
very high concentrations of hexokinase II (more than 100
fold of normal), and especially in the presence of hypoxia
(20, 30). Therefore, the intraarterial administration of 3-
BrPA after inducing tumor hypoxia, such as with balloon
occlusion of the hepatic artery, may increase the therapeu-
tic efficacy to the level seen in in vitro experiments (29).
Preserving the residual liver function is one of most
important prognostic factors for liver cancer (31). It must
be clarified whether 3-BrPA can preserve the normal liver
cell function without significant cytotoxicity even with
administering effective tumoricidal doses. Theoretically,
normal hepatocytes can survive under hexokinase II inhibi-
tion because their energy metabolism does not depend on
a hexokinase II expression. However, our results for the
hepatocellular toxicity of 3-BrPA are not consistent with
the previous in vivo study (22). Geschwind et al. (22) said
that 3-BrPA showed minimal cytotoxicity on normal liver
cells and the near tissues at a low concentration of 0.5 mM
because normal hepatocytes do not express high glycolytic
activity with glucokinase, and there is not much hexoki-
nase II in their cytoplasm (19, 20). It has been reported
that normal liver cells, the portal veins, the sinusoids and
the bile ducts remained completely intact, with the only
apparent damage occasionally occurring in the peribiliary
arteriolar complexes, at much higher concentrations of 5
mM, 3-BrPA (22). In our study, significant elevations of
liver enzymes were noted in the high dose 3-BrPA group,
whereas there was no significant difference of liver
enzymes between the low dose 3-BrPA group and the
control group (p > 0.05). These results imply that 3-BrPA
shows dose-related hepatotoxicity with its intraarterial
administration. Although the hepatic toxicity induced by
intraarterial administration of 3-BrPA did not exceed that
of the Lipiodol-doxorubicin group and the liver enzymes
were nearly normalized within one week in this in vivo
study, higher doses of this agent should be studied to
determine the maximum tolerated dose and the potential
hepatotoxic effect.
This study has several limitations to be mentioned. First,
an investigation concerned with the survival of tumor-
bearing animals was not done. A recent study has shown
that intraarterial infusion of 3-BrPA in VX2 liver tumors
proved to be beneficial due to the significant survival
benefit without any treatment-related toxicity (32).
Further investigations seem to be needed to verify the
drug’s dose-related survival differences. Second, even
though the tumors with similar size were evenly distrib-
uted to each group to exclude any bias, the standard
deviation of the tumor size in each group was relatively
large. However, as a practical matter, the tumor growth
rate is hardly under control and a further study with a
larger population would minimize the size variability. 
In conclusion, intraarterial delivery of 3-BrPA showed a
dose-related antitumor effect and a single session
treatment seems to have limited efficacy when compared
with the conventional TACE. Further studies for determin-
ing the optimal treatment protocol to enhance the
therapeutic effect and to minimize the hepatotoxicity are
warranted. 
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